参考文献/References:
[1] ORVIETO R.Stop GnRH-agonist/GnRH-antagonist protocol:A different insight on ovarian stimulation for IVF[J].Reprod Biol Endocrinol,2023,21(1):13.
[2] VENETIS C A,STORR A,CHUA S J,et al.What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis[J].Hum Reprod Update,2023,29(3):307-326.
[3] ZHU S,LV Z,SONG L,et al.Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment[J].Open Med(Wars),2022,17(1):1811-1820.
[4] HUA L,WANG C.Recombinant-luteinzing hormone supplementation in women during IVF/ICSI cycles with GNRH-antagonist protocol:A systematic review and meta-analysis[J].Eur J Obstet Gynecol Reprod Biol,2023,283(4):43-48.
[5] LI T,LIU X,YANG X,et al.Comparison of the efficacy of depot GnRH agonist protocol and the GnRH antagonist protocol in patients with repeated IVF failure:A retrospective cohort study[J].Hum Fertil(Camb),2023,26(5):1299-1306.
[6] WANG J,ZHANG J,ZHAO N,et al.The effect of ovarian stimulation on aneuploidy of early aborted tissues and preimplantation blastocysts:Comparison of the GnRH agonist long protocol with the GnRH antagonist protocol[J].J Assist Reprod Genet,2022,39(8):1927-1936.
[7] XIAO Z N,PENG J L,YANG J,et al.Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation(PPOS)protocol in patients with polycystic ovary syndrome:Comparison of clinical outcomes and ovarian response[J].Curr Med Sci,2019,39(3):431-436.
[8] 马姣荣,刘成云.促性腺激素释放激素激动剂对保留卵巢根治术患者卵巢功能的影响[J].陕西医学杂志,2020,49(1):24-26,36.
[9] GENG Y,XUN Y,HU S,et al.GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation[J].Gynecol Endocrinol,2019,35(4):309-313.
[10] PAL A,MANI T,CHINTA P,et al.Effectiveness of GnRH agonist short protocol versus GnRH antagonist protocol in POSEIDON groups 3 and 4:A retrospective cohort study[J].Reprod Sci,2023,30(8):2481-2488.
[11] CHEN M X,MENG X Q,ZHONG Z H,et al.An individualized recommendation for controlled ovary stimulation protocol in women who received the GnRH agonist long-acting protocol or the GnRH antagonist protocol:A retrospective cohort study[J].Front Endocrinol(Lausanne),2022,22(13):899000.
[12] QIN Y.Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response:A meta-analysis[J].J Gynecol Obstet Hum Reprod,2021,50(8):102139.
[13] FÀBREGUES F,SOLERNOU R,FERRERI J,et al.Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders[J].JBRA Assist Reprod,2019,23(2):130-136.
[14] GUI J,NI Y,LIU Q,et al.Comparison of clinical effects between early follicular prolonged GnRH agonist protocol and GnRH antagonist protocol in 3310 cycles:A retrospective study[J].BMC Pregnancy Childbirth,2022,22(1):942.
[15] LIU S,LV Y S,HAN S,et al.A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization:Study protocol for a randomized controlled,non-inferiority trial[J].Trials,2022,23(1):654.
[16] ZHAI J,ZHANG J,HE J,et al.Live birth outcomes for PCOS patients under the follicular-phase long-acting GnRH agonist protocol or antagonist protocol-a retrospective chinese cohort[J].J Multidiscip Healthc,2023,16(20):2781-2792.
[17] ZHU J,XING W,LI T,et al.GnRH antagonist protocol versus GnRH agonist long protocol:A retrospective cohort study on clinical outcomes and maternal-neonatal safety[J].Front Endocrinol(Lausanne),2022,13(29):875779.
[18] LIU S,LIU M,LI L,et al.Patients with deep ovarian suppression following GnRH agonist long protocol may benefit from a modified GnRH antagonist protocol:A retrospective cohort study[J].Front Endocrinol(Lausanne),2021,13(12):618580.
[19] MARTINEZ F,CLUA E,ROCA M,et al.Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol:A prospective study with repeated ovarian stimulation cycles[J].Hum Reprod,2022,37(12):2777-2786.
[20] LI Y,DUAN Y,YUAN X,et al.A novel nomogram for individualized gonadotropin starting dose in GnRH antagonist protocol[J].Front Endocrinol(Lausanne),2021,12(14):688654.
[21] YANG L,LUO K,LU G,et al.Euploidy rates among preimplantation genetic testing for aneuploidy cycles with oral dydrogesterone primed ovarian stimulation or GnRH antagonist protocol[J].Reprod Biomed Online,2022,45(4):721-726.
[22] 孙华萍,尹慧琴.GnRH拮抗剂固定方案及GnRH激动剂低剂量长方案对卵巢功能正常不孕患者初次IVF/ICSI治疗研究[J].中国妇幼保健,2020,35(17):3263-3266.
[23] ZHANG L,CAI H,LIU X,et al.Comparison of pregnancy outcomes between GnRH antagonist protocol with freeze-all strategy and long-acting GnRH agonist protocol in women with adenomyosis undergoing IVF/ICSI:A propensity-score matching analysis[J].BMC Pregnancy Childbirth,2022,22(1):946.
[24] YANG R,GUAN Y,PERROT V,et al.Comparison of the long-acting GnRH agonist follicular protocol with the GnRH antagonist protocol in women undergoing in vitro fertilization:A systematic review and meta-analysis[J].Adv Ther,2021,38(5):2027-2037.
[25] CHU Y,WANG L,XIE J,et al.Impact of growth hormone on IVF/ICSI outcomes and endometrial receptivity of patients undergoing GnRH antagonist protocol with fresh embryo transfer:A pilot study[J].Front Endocrinol(Lausanne),2023,14(31):1225121.